Jacob Hyllested-Winge

Jacob Hyllested-Winge has extensive experience in the pharmaceutical industry, particularly in clinical development and medical affairs. At Novo Nordisk from January 2017 to January 2023, Jacob held titles including Project Vice President for the RNAi platform, overseeing siRNA asset development in various therapy areas, and leading the clinical development of CagriSema for obesity. Additionally, Jacob served as Vice President of Medical Operations, where efforts focused on creating a cohesive area promoting trust and transparency. Prior roles included Vice President and Director of Clinical and Regulatory at Pnn Medical A/S, Medical Advisor, and an Orthopaedic Surgery position at Hillerød Sygehus. Jacob also served as Medical Director at Danske Lægers Forsknings Center. Educational qualifications include an M.D. from the University of Copenhagen and an International Baccalaureate from Pearson College.